Tepezza (teprotumumab-trbw)

18F-FAPI & FDG PET/MRI assisting the precise treatment of thyroid-related eye diseases with teprotumumab and evaluating its efficacy, a prospective study (ChiCTR2500113667)

Clinical Efficacy of Teprotumumab in the Treatment of Thyroid-Associated Ophthalmopathy: A Multicenter Prospective Real-World Study (ChiCTR2500112460)

A prospective, randomized controlled study evaluating the efficacy and safety of Teprotumumab versus glucocorticoids in the treatment of thyroid eye disease patients with dysthyroid optic neuropathy (ChiCTR2500112153)

A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Teprotumumab in Thyroid-Associated Ophthalmopathy (TAO) Patients with Clinical Activity Score (CAS) <3 and Radiographically Active Disease (ChiCTR2500111604)

Evaluation of efficacy and safety of teprotumumab combined with glucocorticoids in the treatment of moderate to severe active thyroid eye disease (ChiCTR2500114188)

A Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Teprotumumab (AMG 632) Administered Intravenously in Healthy Chinese Participants (clinicaltrials.gov)

HZNP-TEP-402: TEPEZZA® (Teprotumumab-trbw) Post-Marketing Requirement Study (clinicaltrials.gov)

Comparison of the Efficacy and Safety of 4 vs. 8 Treatments With Tepezza (Teprotumumab) for Thyroid Eye Disease (clinicaltrials.gov)

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease (clinicaltrials.gov)

Effectiveness and Safety of Teprotumumab in patients with thyroid eye disease (ChiCTR2500108068)

HZNP-TEP-305: A Trial to Investigate Teprotumumab Subcutaneous Administration Compared With Placebo in Male and Female Adult Participants With Moderate-to-severe Active Thyroid Eye Disease (clinicaltrials.gov)